Stock comparison
Alignment Healthcare
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALHC
Alignment Healthcare
Market cap
$3.38B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALHC | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 34F | 72B | RMD |
| Benjamin Graham | 68D | 75B | RMD |
| Philip Fisher | 46D | 75B | RMD |
| Peter Lynch | 66B | 58C | ALHC |
| Joel Greenblatt | 43D | 47D | RMD |
| Charlie Munger | 36D | 69B | RMD |
| Terry Smith | 33F | 73B | RMD |
Side-by-side metrics
| Metric | ALHC | RMD |
|---|---|---|
| Market cap | $3.38B | $30.18B |
| P/E (TTM) | 186.4x | 19.6x |
| EV/EBIT | 178.7x | 17.1x |
| ROIC (TTM) | 5.88% | 19.63% |
| Gross margin | 12.38% | 61.69% |
| Net margin | 0.47% | 27.44% |
| Revenue CAGR 5y | 35.6% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 1.6x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALHC leads on
- Revenue CAGR 5y35.6%vs 12.64%+64%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Net margin27.44%vs 0.47%+98%
- Debt / Equity0.1xvs 1.6x+92%
- EV/EBIT17.1xvs 178.7x+90%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.